Seelze, Germany

Norbert Krug

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Helmholtz-Zentrum Fur Infektionsforschung Gmbh. Active years: 2013.



Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Norbert Krug: Innovator in Therapeutical Composition

Introduction

Norbert Krug is a notable inventor based in Seelze, Germany. He has made significant contributions to the field of therapeutical compositions, particularly involving dendritic cells. His innovative work has the potential to impact the treatment of various diseases and disorders.

Latest Patents

Norbert Krug holds a patent for a therapeutical composition containing dendritic cells. The patent describes a method for preparing a therapeutical composition that involves treating dendritic cells with a combination of at least one interferon gamma receptor agonist and at least one toll-like receptor 2 and/or TLR 6 agonist. This method aims to enhance the efficacy of dendritic cells for therapeutic applications.

Career Highlights

Krug is associated with Helmholtz-Zentrum für Infektionsforschung GmbH, where he continues to advance his research in immunology and therapeutics. His work is characterized by a commitment to developing innovative solutions for complex medical challenges.

Collaborations

Some of his notable coworkers include Peter Muhlradt and Henning Weigt. Their collaborative efforts contribute to the ongoing research and development in the field of infection research and therapeutics.

Conclusion

Norbert Krug's contributions to the field of therapeutical compositions highlight his role as an innovator in medical research. His patent on dendritic cell treatment showcases the potential for advancements in therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…